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Abstract 
 
Glycoconjugates are carbohydrates covalently attached to non-sugar components such as proteins and 
lipids. They mediate cell growth, cell-cell communication, cellular differentiation and immune defenses 
in a living organisms. Due to diverse patterns of glycan, glycoconjugates have various applications for 
biomedical purposes. In this thesis, ‘protein cage –based nanoparticles for the recognition and binding 
of cell-surface lectins’, ‘oligosaccharide synthesis for HIV-1 vaccine’, ‘graphene-based biosensor for 
specific lectin detection’, and ‘protein cage-based nanoparticle for delivery vehicles’ are presented. 
Carbohydrates selectively recognize and target endogenous cell-surface lectins. Human ferritin protein 
cage nanoparticles (HFPCNs) are used as targeted-delivery platform for carbohydrate derivatives. 
Maleimide-terminated mannosyl and galactosyl derivatives were synthesized for binding to the surface 
of HFPCNs via thiol-maleimide Michael-type addition. Through fluorescent cell imaging, we 
confirmed specific interaction between polyvalently displayed mannosyl and galactosyl derivatives to 
DCEK and HepG cells, respectively. 
DC-SIGN specifically interact to HIV-1 viruses. DC-SIGN recognizes gp120, a glycan shield on HIV-
1 viruses. To mimic the function of gp120, oligomannosyl derivatives were synthesized. Di-mannosyl 
derivatives were synthesized by glycosylation between glycosyl donor and acceptor. The chemical 
structure of di-mannosyl derivatives were characterized by thin layer chromatography (TLC), nuclear 
magnetic resonance spectroscopy (NMR), and electrospray ionization mass spectrometry (ESI-MS) 
Due to their novel mechanical, electrical, and chemical properties, graphene-based nanomaterials have 
potential for application of biosensors. Graphene-based FET-style biosensor was prepared for the 
recognition of lectin. Pyrene-mannosyl derivatives were synthesized for binding to graphene device and 
recognition of Concanavalin A. Non-covalent - stacking interaction was used in binding between 
graphene device and pyrene-mannosyl derivatives. Through UV-vis, Raman, and atomic force 
microscopic analysis, non-covalent binding was investigated. Graphene-based sensor recognized 
current-voltage characteristic of graphene-based biosensor showed selective recognition of Con A. 
Human heavy-chain ferritin (HHFn) is protein cage-based nanoplatform for delivery of biomolecules. 
The outer surface of HHFn is modified with β-cyclodextrin (β-CD) through thiol-maleimide Michael 
addition followed by copper (I)-catalyzed azide-alkyne cycloaddition (CuAAC). The hydrophobic 
central cavity of β-CD non-covalently interacts to FTIC-AD to form β -CD-C90 HHFn / FITC-AD 
inclusion complexes. FITC-AD is reversibly released from protein cage-based inclusion complexes. 
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Chapter 1. Introduction 
 
1.1 Biological Importance of Carbohydrate 
 
Carbohydrate is one of the four major macromolecules in the biological system.1 Each unit of monomers 
can be combined to one another by various linkage types, and it is possible to make a large number of 
branches. These characteristics allow numerous combinations of glycans.2 Glycoconjugates are 
carbohydrates covalently attached to non-sugar components such as proteins and lipids. In a living 
organism, carbohydrates usually exist as a form of glycoconjugates that mediates cell growth, cell-cell 
communication, cellular differentiation and immune defenses.3 Glycan patterns in glycoconjugates 
determine biological, Chemical and physical characteristics of glycoconjugates.2 
 
1.2 Protein Cage-Based Glyco-Nanomaterials  
 
With the development of nanotechnology, it is possible for nanomaterials, to control sizes, shapes, size 
distributions, and chemical compositions.4-9 Colloidal nanoparticles can carry a large amount of 
materials due to a large surface area and polyvalency. Modifying the surface of nanoparticles with varied 
ligand nanoparticles and enable them to recognize several biomolecules and enhance chemical 
stabilities. Relative large size of Colloidal nanoparticles to free molecules prolong the circulation time 
of drugs.4-9 For these characteristics, Colloidal nanoparticles are promise candidates for targeted 
delivery nanoplatforms.10,11 But it is still hard to reproduce nanoparticles with homogenous 
characteristics due to complicated passivation process and its chemical diversity.12 Protein cage 
structure is the solution to these problems. They tend to self-assemble to form nanoparticles with 
uniform sizes and shapes. Additionally, high order of symmetry and polyvalency of protein cage 
structure allow modifying surface of protein-caged nanoparticles (PCNs) with various ligands.13-17 
PCNs have exterior and interior surfaces. Exterior surfaces are used for polyvalent displaying 
biomolecules like imaging probes and affinity tags. Interior surfaces are used for encapsulating and 
carrying organic materials such as drugs. These surface modifications make PCNs act as cargo loading 
nanoplatforms for targeted delivery.18-24 
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Chapter 2. Protein Cage-based Nanoparticles for the Recognition and 
Binding of Cell-Surface Lectins 
This chapter reproduced with permission of Y. J. Kang et al., Macromolecular Bioscience, 2014, 14, 619.  
Copyright 2014 John Wiley & Sons, Inc. 
Collaboration: All the biological analysis of HFPCNs was done by Young Ji Kang (Prof. Sebuyng Kang group) 
 
2.1 Introduction & Background 
 
2.1.1 Polyvalent Glycan-Displaying Nanoplatforms 
 
Glycans on glycoconjugates specifically interact with lectins on the cell surfaces. These carbohydrate-
protein interaction mediates cell growth, cell-cell communication, cellular differentiation and immune 
defenses.25, 26 Glycans act as definite signs in glycoconjugate for binding to cell-surface lectins.27-29 
But the binding affinity between carbohydrate and lectin is quite weak. Inspired by nature, polyvalent 
glycan interaction was used to overcome this problem.30, 31 Previously, many researchers have studied 
polyvalent glycan displays on various platforms. Polyvalent platforms such as dendrimers, polymers, 
and nanomaterials allow high affinity and specificity to carbohydrate-lectin interactions.32-34 
 
2.1.2 Research objectives 
 
In this study, we synthesize two monosaccharide-derivatives to conjugate human heavy-chain ferritin 
protein cage nanoparticles (HFPCNs) for multimeric glycoconjugate nanoplatforms. These 
monosaccharide-derivatives were attached to the surface of HFPCNs through Michael addition. 
(Scheme 2.1) To synthesize these carbohydrate derivatives, we select thio-glycosyl derivatives due to 
easy formation and chemical stability during reaction process.36 We investigated chemical structures of 
glycosyl derivatives by 1H and 13C nuclear magnetic resonance (NMR) and mass spectrometry (MS) 
and confirmed conjugation of glycosyl derivatives to HFPCNs by mass spectrometry (MS). Finally, we 
presented specific binding of monosaccharide-conjugated HFPCNs by fluorescent cell imaging.
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Scheme 2.1. Synthetic pathway of Gal- and Man- fHFPCNs and their specific recognition to cell 
surface lectins. Reproduced from [35]. 
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2.2 AMM- and AGM- modified HFPCNs  
 
2.2.1 Synthesis of AMM and AGM 
 
Glycosyl bromide was treated by thiourea and hydrolyzed to produce 2,3,4,6-tetra-O-acetyl-1-thio-α-
D-mannopyranoside 1 and 2,3,4,6-tetra-O-acetyl-1-thio-β -D-galactopyranoside 5.37, 38 The thiosugars 
1, 5 were reacted with nitrobenzyl bromide in the existence of TEA. The nitrobenzyl groups were 
reduced by tin chloride to generate (p-aminobenzyl)-2,3,4,6-tetra-O-acetyl-1-thio- α -D-
mannopyranoside 3, and (p-aminobenzyl)-2,3,4,6-tetra-O-acetyl-1-thio-β-D-galactopyranose 7.N-
succinimidyl-3-maleimido-propionate were added to p-anilinyl-linked sugar derivatives to produce 
maleimido group terminated per-acetylated-mannopyranoside (AMM) 4 and maleimido group 
terminated per-acetylated-galactopyranoside (AGM) 8 (Scheme 2.2).39, 40 
 
Scheme 2.2. Synthetic scheme of AMM and AGM: a) 4-nitrobenzyl bromide, DMF, TEA, r.t., Man 
81%, Gal 90%; b) SnCl2–2H2O, EtOH, 70 °C, Man 44%, Gal 50%; c) N-succinimidyl 3-maleimido-
propionoate, DMF/(DCM), DIPEA, Man 73%, Gal 52%. DMF, N,N-dimethylformamide; DCM, 
dichloromethane; DIPEA, N,N-diisopropylethylamine; TEA, triethylamine. Reproduced from [35]. 
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2.2.2 Conjugation of AGM and AMM to HFPCNs 
 
We used human ferritin as a template for the synthesis of protein-cage based nanoplatform for targeted-
delivery.41-46 24 subunits of Human heavy-chain ferritin protein cage nanoparticles (HFPCNs) have 
cysteine residue (C90) on their exterior surface.39 These cysteines can be modified by other functional 
moieties. We conjugated maleimido group terminated per-acetylated-mannopyranoside (AMM, AGM) 
to the cysteine moieties on the surface of HFPCNs (Scheme 2.1). AMM and AGM have acetyl groups 
that protect hydroxyl groups. To deprotect the acetyl groups to hydroxyl groups, we dialyzed AMM- or 
AGM-modified HFPCNs overnight at pH 11.47 
 
2.3 Characterization of Man-HFPCNs and Gal-HFPCNs 
 
We investigated the presence of hydroxyl groups on HFPCNs using electrospray ionization-time of 
flight mass spectrometry (ESI-TOF MS) to investigate the completion of deacetylation.18,22 The 
molecular masses of each subunit of AMM- or AGM- modified HFPCNs was 21,683.0 Da, which 
corresponded to the calculated value (21,682.5 Da) (Figure 2.1). Both AMM- and AGM- modified 
HFPCNs showed same molecular mass because they have the same composition of the atoms. From 
this data, we found that each subunit of HFPCNs has one AMM or AGM on their surface (24 AMMs 
or AGMs per cage). During reaction, we collected each modified HFPCN samples at several points and 
measured the molecular masses of the samples to check the process of deacetylation. As one acetyl 
group in AMM or AGM moiety on HFPCNs is deprotected to the hydroxyl group, they have mass 
decreases of 42 Da. The molecular mass data showed the gradual mass decrease of modified HFPCNs 
as reaction proceeds (Figure. 2.2). After end of deacetylation, modified HFPCNs had final molecular 
mass of 21,533.0 Da, which had a minor error compared with the calculated value (21,514.5 Da) (Figure 
2.1 and Figure 2.2). Previous article reported that oxidation of thioether groups caused this error.48 
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Figure 2.1. Electrospray ionization-time of flight mass spectrometry of each subunit of (A) AMM-
HFPCN (calcd. 21 682.5 Da, obs, 21 683.0 Da), (B) Man-HFPCNs (calcd., 21 514.5 Da, obs, 21 533.0 
Da), (C) AGM-HFPCN (Calcd, 21682.5 Da, obs, 21683.0 Da) and (D) Gal-HFPCNs (Calcd, 21514.5 
Da, obs, 21533.0 Da). Reproduced from [35]. 
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Figure 2.2 Gradual mass decrease of (A) Man-HFPCN, (B) AMM-HFPCN, (C) Gal-HFPCN (D) 
AGM-HFPCN at various point (0hr, 1hr, 6hr, 15hr, 24hr, and 48hr). AGM-HFPCN incubated at pH 
11 for different time. Observed masses were shown in a below table. Reproduced from [35]. 
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2.4 Targeted Delivery of Modified HFPCNs 
 
2.4.1 Cell-Surface Lectins 
 
In targeted delivery of biomolecules to particular cells, cell-surface lectins act as a marker due to their 
high specificity in binding to glycans.27-29 we selected DC-SIGN and asialoglycoprotein receptor 
(ASGP-R) as target lectins for delivery of Man-HFCPCNs and Gal-HFPCNs to specific target cells. 
Dendritic cells (DCs) has DC-SIGN, a C-type lectin on their surface. DC-SIGN recognizes mannose- 
and fucose-type glycans on glycoproteins.28, 49 As a pattern recognition receptor, DC-SIGN binds to 
carbohydrate a moiety on HIV-1 and Mycobacterium tuberculosis, inducing immune responses in 
human immune system.49 ASGP-R is an endocytotic receptor present on the surface of hepatocytes. It 
explicitly identifies galactose-containing glycoproteins and mediates endocytosis for targeted delivery 
of genes and drugs.50 
 
2.4.2 Fluorescent Cell Imaging Analyses of Modified HFPCNs 
 
We treated Man-HFPCNs and Gal-HFPCNs with N-hydroxysuccinimide (NHS)-ester-fluorescein to 
observe lectin-targeted delivery of nanoparticles to specific cells. We prepared DCEK cells, and HepG2 
cells, which have DC-SIGN and ASGP-R on their surface, respectively.51, 52 Fluorescent labeled Man-
HFPCNs and Gal-HFPCNs (fMan-HFPCNs and fGal-HFPCNs) were detected by fluorescence 
microscopy to confirm specific recognition between mannose- and galactose-modified HFPCNs and 
target lectin. For negative controls, we also labeled AMM-HFPCNs and AGM-HFPCNs with NHS-
ester-fluorescein (fAMM-HFPCNs and fAGM-HFPCNs) because AMM and AGM don’t interact to 
cell-surface lectins. 
We investigated specific carbohydrate-lectin binding between fMan-HFPCNs and DCEK cells, and 
fGal-HFPCNs and HepG2 cells through fluorescent microscopy. (Figure 2.3A, B bottoms). However, 
in cases of fAMM-HFPCNs and fAGM-HFPCNs, there were no carbohydrate-lectin interaction (Figure 
2.3 A, B tops). From these data, we demonstrated that mannose and galactose moieties on HFPCNs 
selectively recognize target lectins on the cell surfaces, DC-SIGN and ASGP-R, respectively. 
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Figure 2.3. Fluorescent microscopic images of (A) DCEK cells and (B) HepG2 cells. DCEK cells 
were stained with fMal-HFPCN (bottom, left) and fAMM-HFPCN (top, left). HepG2 cells were 
stained with fGal-HFPCN (bottom, left) and fAGM-HFPCN (top, left) Nucleus was treated with 
DAPI (top and bottom, right). Reproduced from [35]. 
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2.5 Conclusions 
 
We conjugated AMM and AGM to HFPCNs, which had 24 cysteine residues on their surface. From 
mass spectrometry analysis, we confirmed uniform and polyvalent displays of monosaccharide 
derivatives on the surface of HFPCNs. Fluorescent cell imaging data demonstrate specific 
carbohydrate-lectin binding and targeted delivery of modified HFPCNs. Man-HFPCNs and Gal-
HFPCNs specifically bound to DC-SIGN on DCEK cells and ASGP-R on HepG2 cells, respectively. It 
is also possible to modify the interior cavity of HFPCNs. Biomolecules such as medicinal drugs and 
imaging probes can be conjugated on the interior surface of HFPCNs.15, 53 Through both exterior and 
interior surface modification, we can advance multifunctional protein cage nanoparticles for targeted 
drug delivery. 
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Chapter 3. Oligosaccharide synthesis for HIV-1 vaccine 
 
3.1 Introduction & Background 
 
3.1.1 DC-SIGN: Receptor for HIV-1 
 
HIV-1 is one of the fatal disease which infect about 60 million and killed over 20 million people.54, 55 
This virus attacks an immune system in the human body, making them immune deficiency.56 HIV-1 
viruses have glycan shield on their surfaces, so-called gp120, which help to invade target T-cells.57, 58 
The interaction between gp120 and T-cell is key for viral invasion of HIV-1.59 DC-SIGN (Dendritic 
Cell-specific Intercellular adhesion molecule-3-Grabbing Non-integrin) is one of the HIV-1 receptor 
recognizing mannose-containing glycan shield of HIV-1 presented on the surface of dendritic cells.60 
When a complex between HIV-1 and DC-SIGN formed, these complex attacks the CD4+T cell and led 
productive T cell infection.28 
 
3.1.2 Research Objectives 
 
In this research, we observed immunogenic effect of oligomannose-modified protein cage nanoparticles, 
specifically interaction to DC-SIGN. We synthesized oligomannose which mimic gp120, glycan shield 
on HIV-1 virus. For the oligosaccharide synthesis, we prepared glycosyl donor and acceptor first and 
linked them through glycosylation. The chemical structures of glycosyl donor, acceptor, and 
oligomannose were confirmed through 1H nuclear magnetic resonance (NMR) and mass spectrometry 
(MS) analysis. 
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3.2 Synthesis of Mannosyl Derivatives 
 
3.2.1 Synthesis of Glycosyl Donor and Acceptor 
 
To build up disaccharide derivatives, 2-O-Acetyl-3,4,6-tri-O-benzyl--D-mannopyranosyl 
trichloroacetimidate 8 and 2’-azidoethyl-3,4,6-tri-O-benzyl--D-mannopyranoside 10 were selected as 
glycosyl donor and acceptor, respectively. They were prepared from D-mannose through several 
processes (Scheme 3.1). First, hydroxyl groups of D-mannose were acetylated by acetic anhydride and 
iodine. Acetylated mannose was treated with hydrogen bromide solution for substitution of the acetyl 
group in anomeric position with bromine. 2,3,4,6-tetra-O-acetyl--D-mannopyranosyl bromide 2 was 
reacted with methanol to generate Exo-3,4,6-tri-O-acetyl-1,2-O-(1-methoxyethylidene)- β -D-
mannopyanoside 3. Mannosyl orthoester derivative 3 was deacetylated under Zemplen condition, 
followed by the benzylation with BnBr. Exo-3,4,6-tri-O-benzyl-1,2-O-(1-methoxyethylidene)- β-D-
mannopyranoside 5 was treated with acetic acid and acetic anhydride to produce 1,2-Di-O-acetyl-3,4,6-
tri-O-benzyl-D-mannopyranose 6. 2-O-Acetyl-3,4,6-tri-O-benzyl--D-mannopyranose 7 was 
generated by selective anomeric deacetylation of 6 with benzylamine. 2-O-Acetyl-3,4,6-tri-O-benzyl-
α-D-mannopyranose 7 was reacted to trichlroaceointrile to generate glycosyl donor, 2-O-Acetyl-3,4,6-
tri-O-benzyl--D-mannopyranosyl trichloroacetimidate 8. Glycosyl donor 8, was reacted with 2-
azidoethane and subsequently deacetylated to produce glycosyl acceptor, 2’-azidoethyl-3,4,6-tri-O-
benzyl-α-D-mannopyranoside 10. 
 
 
 
13 
 
 
Scheme 3.1. Synthetic scheme of glycosyl donor 8 and glycosyl acceptor 10. (a) Ac2O, RT, quantitative 
yield; (b) HBr, RT, 91%; (c) MeOH, DCM, 40 ˚C, 91%; (d) NaOMe, MeOH, RT, 75%; (e) BnBr, NaH, 
DMF, RT, 63%; (f) H2O, AcCOOH, pyridine, Ac2O, RT, 80%; (g) BnNH2, THF, RT, 78.5%; (h) 
Trichloroacetonitrile, DCM, 1,8-Diazabicyclo[5,4,0]undec-7ene, RT, 64%; (i) 2-azidoethanol, 
TMSOTf DCM, RT, 80.5%; (j) NaOMe, MeOH, RT, 100%, quantitative yield. 
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3.2.2 Glycosylation 
 
Disaccharide is synthesized by linking of two monosaccharide precursors by formation of glycosidic 
linkage. Glycosidic bond is formed by displacement of a leaving group at the anomeric position of 
glycosyl donor 8 with a free hydroxyl group of glycosyl acceptor 10. Activated with Lewis acid, they 
provide disaccharide in good yields (48%). After glycosylation, disaccharide was deprotected under 
Zemplen condition followed by a debenzylation with Pd/C and hydrogen gas. (Scheme 3.2).  
 
 
Scheme 3.2 Glycosylation between glycosyl donor 8 and acceptor 10. (a) TMSOTf, DCM, RT, 48.3%; 
(b) i) NaOMe, MeOH, RT; ii) Pd/C, H2(g), MeOH, RT, 89%.  
 
3.3 Characterization of Mannosyl Derivatives 
 
We confirmed the chemical structure of 2-aminoethyl-α-D-mannopyranosyl-(1→2)-α-D-
mannopyranoside 12 by 1H nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry 
(MS) (Figure 6.14). Anomeric proton peak of each mannosyl unit were observed at 5.0 ppm and 5.1 
ppm to indicate glycosyl donor and acceptor were connected successfully. Broaden peak at 3.15-3.25 
ppm shows characteristics of amine peak. This peak suggested that azide group in 2’-azidoethyl-2-O-
acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl-(1→2)-3,4,6-tri-O-benzyl-α-D-manno-pyranoside 11 
was reduced by hydrogen gas purging. The observed molecular mass data of dimannosyl amine 
derivative was 386.21 Da, which corresponded to the calculated value (386.17 Da). These data 
demonstrated the presence and high purity of our product. 
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3.4 Conclusions 
 
We synthesized glycosyl donor and acceptor for glycosylation of dimannosyl amine derivative. 
Dimannosyl amine derivative was characterized by NMR, MS analysis. In the future, we should convert 
amino group to azide group and synthesize maleimide-alkyne linker for conjugation to the virus-like 
particles. The complex of disaccharide and virus-like particles will be used to test an immune response 
against DC-SIGN. 
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Chapter 4. Graphene-based Biosensor for Specific Lectin Detection 
 
Collaborations: Preparation of graphene device and electrical analysis was done by Mi-Sun Lee (Prof. Jang-Ung Park 
group) 
 
4.1 Introduction & Background 
 
4.1.1 Graphene-Based Biosensor 
 
Graphene is a single atom-thick, two-dimensional lattice of sp2-hybridized carbon atoms. Owing to 
its excellent mechanical, electronic, optical and thermal properties, graphene has been attracting 
considerable interest in various scientific fields.61, 62 In specific, graphene has potential for applications 
in FET (Field effect transistor)-style biosensors due to its high-sensitivity, high-flexibility, cost 
effectiveness and easy surface modification.63 Graphene-based biosensors detect biomolecules with 
high-selectivity and low-noise levels.64-66 Recently, carbohydrate has been used as the components of 
graphene biosensor. In a living organism, carbohydrate mediates cell growth, cell-cell communications, 
cellular differentiations and immune responses.1-3 Modified by carbohydrate moieties, graphene-based 
biosensor can detect specific lectins.67 
 
4.1.2 Covalent and Non-covalent Modification 
 
Both covalent and non-covalent modification has been used to attach biomolecules to graphene-based 
FET. Covalent modifications, such as oxidation, give strong bonding between biomolecules and    
graphene. But it breaks down sp2 planar structures of graphene to sp3 structures. On the contrary, non-
covalent modification preserves structure of graphene and its intrinsic properties. Recently, non-
covalent - stacking interaction has been widely used in chemical modification of graphene.68 
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4.1.3 Research Objectives 
 
In this research, we designed a graphene-based FET biosensor to detect Concanavalin A (Con A), 
which specifically interacts to mannose. We conjugated glyco-pyrene derivatives to FET-style 
graphene devices via - stacking interaction. This glyco-pyrene graphene complex was expected to 
monitor the reversible interaction between Concanavalin A and mannosyl moiety as graphene-based 
biosensor. 
 
4.2 Synthesis of Graphene-Based Biosensor 
 
4.2.1 Synthesis of Glyco-Pyrene Derivatives 
 
We selected thio-glycosyl derivative 1 and 4 as starting compound for the synthesis of glycol-pyrene 
derivatives. (Scheme 1) Thio-glycosyl derivatives are chemically stable, so they don’t break during 
organic reactions.36 p-Aniliyl type termini in thio-glycosyl derivatives helps - stacking interaction 
because of its aromatic ring. We conjugated 1-pyrenebutyric acid to aniliyl termini through 
amide bond formation. Then, we deprotected acetyl groups in 2 and 5 under the Zemplen condition 
to generate glyco-pyrene derivatives 3 and 6. 
 
 
Scheme 4.1. Synthesis of glyco-pyrene derivatives. (a)/(c) 1-pyrenebutyric acid, DMF, TBTU, TEA, 
RT, Mannosyl 2: 82%, Galactosyl 5: 57%; (b)/(d) NaOMe, MeOH, RT, Mannosyl pyrene 3: 99%, 
Galactosyl pyrene 6: 99%. DMF: N,N-dimethylformamide, TBTU: O-(Benzotriazol-1-yl)-N,N,N′,N′-
tetramethyluronium tetrafluoroborate, TEA: triethylamine, RT: room temperature. 
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4.2.2 Conjugation of Glyco-Pyrene Derivatives to Graphene-Based FET 
 
Graphene-based FET was incubated by solution of in methanol (2 g/L) at RT. After 12 h, 
excess glyco-pyrene derivatives were washed by methanol and graphene-based FET was dried. 
 
4.3 Characterization of Graphene-Based Biosensor 
 
4.3.1 Characterization of Glyco-Pyrene Derivatives 
 
We investigated the chemical structure of glyco-pyrene derivatives 3 and 6 through 1H and 13C 
nuclear magnetic resonance (NMR) and mass spectrometry (MS) analysis (Figure 
5.1). We confirmed the presence of pyrene moiety by observing aromatic C-H peaks at 7.5-8.4 ppm. 
Additionally, we found characteristic mannosyl and galactosyl peaks at 3.0-5.0ppm. The detailed 
chemical structure of glyco-pyrene derivatives 3 and 6 were characterized by two-dimensional NMR 
spectroscopy such as correlation spectroscopy (COSY) and heteronuclear single quantum coherence 
spectroscopy (HSQC) (figure 6.15-6.20 in Experimental 6.4). 
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Figure 4.1. 1H NMR (600 MHz, DMSO-d6) spectra of glyco-pyrene derivatives 3 (a) and 6 (b). 
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4.3.2 Characterization of Non-Covalent - Stacking Interaction 
 
4.3.2.1 UV-Vis Spectroscopy 
 
We confirmed non-covalent - stacking interaction between mannosyl-pyrene derivatives 3 and 
graphene-based FET by UV-Vis spectroscopy (Figure 5.2a). UV-Vis spectra of mannosyl pyrene 3 
shows characteristic pyrene peaks at 335 and 351 nm. However, after non-covalent modification of 
graphene with mannosyl pyrene 3, each pyrene peaks were shifted to 332 and 348 nm, respectively. 
These data indicate that the non-covalent interaction between pyrene moieties and graphene affects UV-
Vis spectra of mannosyl pyrene-graphene. 
 
4.3.2.2 Raman Spectroscopy 
 
We investigated Raman spectra of pristine graphene and graphene non-covalently modified with 
mannosyl pyrene 3. The G band in pristine graphene was observed at 1588 cm-1. After incubating the 
graphene with mannosyl-pyrene derivatives, the G band was found at 1592 cm-1 with slight blue-shift. 
This shift suggests that charge-transfer interaction occur between graphene and pyrene moieties as 
previous researches demonstrated.67, 68      
 
Figure 4.2. UV-Vis spectra (c) and Raman spectra (d) of mannosyl-pyrene derivative 3. 
 
 
21 
 
4.3.2.3 Atomic Force Microscopy 
 
Atomic force microscopy (AFM) was used to confirm the non-covalent binding between graphene and 
mannosyl-pyrene derivatives. AFM images of pristine graphene film and graphene film incubated with 
mannosyl-pyrene derivative 3 reveal that the thickness of pristine graphene film was ~4 nm while that 
of graphene film incubated with mannosyl-pyrene derivative 3 was ~5nm with some noises (figure 4.2). 
 
 
Figure 4.3. AFM images and the height profiles of pristine graphene (a, c) and graphene incubated with 
mannosyl-pyrene derivative 3 (b, d), respectively. 
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4.4 Characterization of Lectin Recognition 
 
We investigated current-voltage characteristics of graphene device incubated by glycol-pyrene 
derivatives followed by Concanavalin A (Con A) to confirm selective interaction between mannose and 
Con A. When Con A was incubated on mannosyl-pyrene-coated graphene device, ID-VG curve shifted 
(Figure 4.3 a) while no change occurred in ID-VG curve of galactosyl-pyrene-coated graphene device 
(Figure 4.3 b). To demonstrate reversible binding of con A and mannose, we flew con A and excess 
mannose alternately to graphene device. In the case of the mannosyl-pyrene-coated graphene device, 
there was ID-VG curve shift as con A was bound and repeatedly detached, but there was no change in 
the galactosyl-pyrene-coated graphene device (Figure 4.3 c). These data suggest that Con A interacts to 
only mannose specifically. 
Figure 4.4. ID-VG curve of graphene-based biosensor. (a) After incubation of mannosyl-pyrene 
derivative 3 and Concanavalin A on graphene. (b) After incubation of galactosyl-pyrene derivative 6 
and Concanavalin A on graphene (negative control). (c) Repeated binding and detaching of 
Concanavalin A on graphene device by alternate flow of Concanavalin A solution and excess amount 
of D-mannose.   
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4.5 Conclusions 
 
In this research, we synthesize glyco-pyrene derivatives to conjugate graphene device for graphene-
based FET style biosensor. Glyco-pyrene derivatives were bound to graphene through non-covalent -
 stacking interaction. Chemical structure of glycol-pyrene derivatives were confirmed by 1H and 13C 
nuclear magnetic resonance (NMR) and mass spectrometry (MS). UV-Vis, Raman, and atomic force 
microscopic analysis (AFM) demonstrate non-covalent binding between mannosyl-pyrene derivatives 
and graphene device. But, it is needed to investigate loading concentration of glycol-derivatives and 
concanavalin A on graphene. From controlling loading concentration of carbohydrate and protein, we 
can investigate how concentration affects the electrical characteristic of graphene-based biosensor. 
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Chapter 5. Protein Cage-based Nanoparticles for delivery vehicles  
This chapter reproduced with permission of C. Kwon et al., Macromolecular Bioscience, 2012, 12, 1452  
Copyright 2014 John Wiley & Sons, Inc. 
Collaborations: All the biological analysis of HHFns was done by Young Ji Kang (Prof. Sebuyng Kang group) 
 
5.1 Introduction & Background 
 
5.1.1 HHFn: Protein-Caged Nanoplatforms  
 
Human heavy chain ferritin (HHFn) is protein-caged nanoparticles consist composed of 24 identical 
subunits. Self-assembly of 24 subunits give hollow cage structure to HHFn with outer diameter 12 mm 
and inner diameter 8 mm.69 Previously many researchers have studied an application of HHFn as 
biomimetic nanoscale vehicles for targeted delivery.41-46 HHFn with uniform characteristics is easily 
reproduced due to simple control of sizes, and shapes.69 Additionally, inner and outer surface 
modification give HHFn many advantageous characteristics for targeted delivery.13-24 
 
5.1.2 β-Cyclodextrins   
 
β -Cyclodextrins (β-CDs) is 7-membered ring carbohydrates. β-Cyclodextrin is used for encapsulating 
and delivering non-polar molecules in aqueous condition due to different polarity of exterior and interior 
surfaces. On the exterior surface of β-CD, a number of hydroxyl groups exist. These hydroxyl groups 
make β-CD soluble in water. On that contrary, the interior surface of β-CD is hydrophobic. These 
characteristics make reversible binding and releasing non-covalently between β-CD and non-polar 
molecules.70, 71 
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5.1.3 Click Chemistry  
 
Protein cage-based nanoparticles (PCNs) are used for targeted delivery of biomolecules. These 
biomolecules are attached to surface of PCNs via covalent linkages. But most of these linkages are 
easily broken down in living organisms.13, 21 Copper (I) catalyzed azide-alkyne cycloaddition (CuAAC) 
so-called click chemistry is widely used in a biological system because of its bioorthogonality and 
chemical stability in aqueous condition. Azide and alkyne pairs react each other in mild and aqueous 
conditions, giving high yield of products.72, 73 For these novel characteristics of click chemistry, it has 
the potential for application of drug delivery and discovery in medicinal chemistry.74 
 
5.1.4 Research Objectives 
 
In this research, we utiltized human heavy chain ferritin (HHFn) as a nanoplatform for targeted delivery. 
Each subunit of HHFn has one cysteine moiety on their surface. We conjugate β-cyclodextrins (β-CDs) 
to thiol groups in cysteines through CuAAC and subsequent Michael addition. (Scheme 5.1) Finally, 24 
β-cyclodextrins are adhered on the surface of single cage structure of HHFn. We investigate the 
chemical structure of β-CD-modified HHFns by mass spectrometry. We demonstrate reversible 
inclusion and release of fluorescein isothiocyanate-conjugated adamantine (FITC-AD) in β-CDs 
through UV-Vis spectrometry.        
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Scheme 5.1. Synthetic process of of β-CD-C90 HHFn/FITC-AD Inclusion Complex. β-CDs are 
uniformly presented on the surface of C90 HHFn through Michael addition and CuAAC. 
The inclusion complex is formed with FITC-AD. Reproduced from [39]. 
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5.2 Synthesis of β-CD-C90 HHFn/FITC-AD Inclusion Complex 
 
5.2.1 Synthesis of β-CD-N3 
 
β-Cyclodextrin-hydrate was treated with 1-(p-toluenesulfonyl)imidazole) for selective tosylation of 
hydroxyl groups. Subsequently, sodium methoxide was added to the reaction mixture to generate Mono-
6-(p-toluenesulfonyl)-6-deoxy- β-cyclodextrin (β-CD-Ts) 1. After completion of the reactants, 
ammonium chloride was added to quench the reaction.75 To substitute tosyl group with the azide group, 
β-CD-Ts 1 was reacted with sodium azide. The reaction mixture was concentrated and treated with 
1,1,2,2-tetrachloroethane. Centrifugation and recrystallization were used to purify mono-6-azide-
deoxy-6- β –cyclodextrins (β-CD-N3) 2.76 We confirmed the molecular structure of β-CD-Ts and β-CD-
N3 by 1H and 13C nuclear magnetic resonance (NMR) spectrometry and mass spectrometry (Figure 6.22 
in Experimental 6.5). Purity of β-CD-Ts and β-CD-N3 were investigated by thin layer chromatography 
(TLC). Each sample of β-CD, β-CD-Ts, and β-CD-N3 showed quite pure spot in silica plate with a few 
impurity. (Figure 5.1) 
 
 
Scheme 5.2. Synthesis of Mono-6-azide-deoxy-6-β-cyclodextrin (β-CD-N3) 2. (a) 1-(p-
toluenesulfonyl)imidazole, NaOH, 60 °C; (b) NaN3, 100 °C. Reproduced from [39]. 
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Figure 5.1. Thin layer chromatography (TLC) analysis of β-CD, β-CD-Ts, and β-CD-N3. Running 
solvent consists of iso-propanol, water, ethanol, ammonium hydroxide with the ratio of 5:3:1:1. 
Reproduced from [39]. 
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5.2.2 Synthesis of N-Propargyl 3-maleimido-propionamide (PMP) 
 
Maleic anhydride was treated with β-alanine at RT to generate 3-Maleimido propionic acid 1. 3-
Maleimido propionic acid 3 was reacted to N-hydroxysuccinimide (NHS) ester with DCC. In this 
process, carboxyl acid in Maleimido propionic acid 3 reacted to the primary amine in N-
hydroxysuccinimide (NHS) ester to form amide bond in succinimido 3-maleimido-propionate 4.40 The 
NHS group in succinimido 3-maleimido-propionate 4 was substituted with propargylamine to generate 
N-Propargyl 3-maleimido-propionamide (PMP) 5. The structure of PMP was confirmed by 1H and 13C 
nuclear magnetic resonance (NMR) spectrometry and mass spectrometry. (Figure 6.21) 
 
 
Scheme 5.3. Synthesis of N-Propargyl 3-maleimido-propionamide (PMP) 5. (a) β-alanine, RT ; (b) 
DCC, NHS, 0°C→RT, 50%; (c) propargylamine, 0°C→RT, 6%. Reproduced from [39]. 
 
5.2.3 Synthesis of β-CD-C90 HHFn  
 
Originally, each subunit of wild-type HHFn had three cysteine moieties (C90, C102, and C130) on the 
exterior surface. Two cysteines (C102, C130) were substituted by serine moieties (C102S, C130S) to 
prevent steric hindrance in conjugation between HHFn and β -CDs. Therefore, only one cysteine moiety 
(C90) reacted to β-CDs.69 In order to conjugate β-CD to C90 HHFn on the precise position, C90 HHFn 
was treated with N-propargyl-3-maleimidopropionamide (PMP). Maleimide group in PMP reacted to 
C90 cysteine group through maleimide-thiol Michael-type addition.40 Finally, Alkyne group in C90 
HHFn was reacted to β-CD-N3 with tris(3hydroxypropyltriazolylmethyl)amine (THPTA), a Cu ligand 
by copper(I) catalyzed azide-alkyne cycloaddition (CuAAC) to form β-CD-C90 HHFn.(Scheme 5.1) 77  
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5.2.4 Synthesis of β-CD-C90 HHFn/FITC-AD Inclusion Complex 
 
Since β-CD can encapsulate small hydrophobic molecules in its interior cavity, β-CD-C90 HHFn has a 
potential for application in targeted delivery nanoplatform.70, 71 We synthesized inclusion complex of β-
CD-C90 with guest molecules. FITC-AD was chosen as guest molecules due to its fluorescence and 
non-covalent interaction to β-CD. To synthesize FITC-AD, we conjugate 1- adamantylamine to 
fluorescein isothiocyanate (FITC) with a mild base. (Scheme 5.4).78 In FTIC-AD, adamantyl group non-
covalently interacts to β-CD with a high association constant (105L mol-1) and FITC group emits green 
fluorescent light to track the guest molecules.78 β-CD-C90 HHFn was treated with FITC-AD to form 
FITC-AD/ β-CD/C90 HHFn inclusion complexes (Scheme 5.1). 
 
  
Scheme 5.4. Synthesis of FITC-AD conjugate. Reproduced from [39]. 
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5.3 Charcterization of β-CD-C90 HHFn/FITC-AD Inclusion Complex 
 
5.3.1 Characterization of β-CD-C90 HHFn  
 
The formation of 1,2,3-triazole ring between HHFn subunit and β-CD-N3 was investigated by 
electrospray ionization-time of flight mass spectrometry (ESI-MS TOF) (Figure 5.2A).18, 22 The charge 
state affects to measure molecular mass of proteins. But in this case, the change of charge state was 
small enough to ignore. We assume that the charge distribution of chemically modified HHFn and 
unmodified HHFn were nearly same.18, 22 The molecular masses of each subunit of unmodified C90 
HHFn was 21064.0 Da, which corresponded to the calculated value (21062.3 Da). After treating PMP 
5 to C90 HHFn, the molecular mass increased by 206.0 Da. (Figure 5.2 middle). Subsequently, after β-
CD addition, the molecular mass increased by 159.0 Da. These data showed that all the C90 HHFn 
subunits were conjugated to PMP 5, and reacted to β-CD-N3 to form 1,2,3-triazole ring via CuAAC. 
The cage-like structure of β-CD-C90 HHFn were confirmed by transmission electron microscopy (TEM) 
(Figure 5.3A). TEM image showed outer diameter of β-CD-C90 HHFn was 13 nm. We investigate the 
mean hydrodynamic diameter of β-CD-C90 HHFn by dynamic light scattering (DLS). The mean 
hydrodynamic diameter of β-CD-C90 HHFn was 15.6mm, which is longer than that of unmodified C90 
HHFn (12 mm).69 From these TEM images and dynamic light scattering data, it seems that β-CD-C90 
HHFn retain cage-like structure after conjugation of maleimide linker and CuAAC reactions..  
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Figure 5.2. Molecular mass analyses of subunits of β-CD-N3-clicked C90 HHFn (top), PMP-treated 
(middle), and C90 HHFn (bottom). Reproduced from [39]. 
 
 
 
Figure 5.3. (A) TEM image of β-CD-C90 HHFn stained with 2% uranyl acetate. (B) DLS measurement 
of β-CD-C90 HHFn (mean diameter: 15.6 nm). Reproduced from [39]. 
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5.3.2 Characterization of β-CD-C90 HHFn/FITC-AD Inclusion Complex 
 
We investigated non-covalent interaction between FITC-AD and β-CD-C90 HHFn by UV-Vis 
spectrometry. We treated FITC-AD to β-CD-C90 HHFn and C90 HHFn at RT and remove the excess 
FITC-AD by PD-10 desalting columns. C90 HHFn was used as negative controls because they do not 
interact to FITC-AD. After purification, FITC-AD-treated β-CD-C90 HHFn shows green color, while 
FITC-AD-treated C90 HHFn shows no color (figure 5.4B). In the UV/Vis spectra of FITC-AD-treated 
β-CD-C90 HHFn, characteristic fluorescein peaks were observed at 495 nm. (Figure 5.4A solid line) 
But, in case of C90 HHFn, there was no peak observed at 495 nm. (Figure 5.4A dashed line). These 
data indicates that β-CDs on the surface of C90 HHFn encapsulate FITC-AD and β-CD-C90 
HHFn/FITC-AD inclusion complex are successfully formed. To investigate the deformation of FITC-
AD/β-CD-C90 HHFn inclusion complexes, we checked the change of absorbance of FITC-AD peak by 
UV/Vis spectrophotometer during dialysis. FITC-AD/β-CD-C90 HHFn inclusion complex was 
dialyzed at RT. We collected and analyzed the sample at varying times. As FITC-AD released, 
absorbance of FITC-AD decreases indicating that FITC-AD/β-CD-C90 HHFn inclusion complex was 
decomposed (Figure 5.5A). The release of FITC-AD was getting slower showing exponential decay 
curve. (Figure 5.5B) These results indicate that β-CD-C90 HHFn can release FITC-AD reversibly as 
well as encapsulate FITC-AD and FITC-AD/β-CD-C90 HHFn have a potential for application of 
nanoplatform for targeted delivery.  
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Figure 5.4. (A) UV/Vis spectra of FITC-AD-treated β-CD-C90 HHFn (solid line) and C90 HHFn 
(dashed line) (B) PD-10 desalting column elutes of FITC-AD treated C90 HHFn (left) and β-CD-C90 
HHFn (right). Reproduced from [39]. 
 
 
Figure 5.5. (A) UV/Vis spectra FITC-AD from the FITC-AD/β-CD-C90 HHFn inclusion complexes 
during dialysis. Samples were measured at 0, 10, 20, and 40 min, 1, 2, 4, 9, 13, and 22 h. (B) Release 
profile of FITC-AD. Reproduced from [39]. 
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5.4 Conclusions 
 
We used β-CD-C90 HHFn as a nanoplatform for delivery of insoluble molecules. β-CD was conjugated 
to C90 HHFn through Michael-type addition followed by CuAAC. β-CD-C90 HHFn formed inclusion 
complex with FITC-AD, which was released reversibly. FITC-AD/β-CD-C90 HHFn inclusion complex 
showed capability of delivering FITC-AD for only short time. Since β-CD-C90 HHFn has additional 
site in the interior cavity, modifying internal cavity will be the solution to the time problem. In the future, 
we can conjugate β-CD to other types of protein cages to develop multifunctional protein cage-based 
nanoplatforms for targeted delivery. 
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Chapter 6. Experimental 
 
6.1 General 
 
Chemical Characterizations 
 
Proton nuclear magnetic resonance (δH) spectra and carbon nuclear magnetic resonance (δC) spectra 
were recorded by using an Agilent 400-MR DD2 spectrometer. Low resolution mass spectra were 
recorded on a Bruker HCT Basic System using electrospray ionization (ESI). High resolution mass 
spectra were recorded on a ABI API-3000 electrospray ionization mass spectrometer. Optical rotations 
were measured on a ATAGO AP-300 automatic polarimeter with a path length of 1 with expressing 
concentrations in g/100 mL. Thin layer chromatography (TLC) was carried out on Merck silica gel 
60F254. Visualization of the plates was achieved using an ultraviolet lamp (254 nm) and/or potassium 
permanganate (0.5% in 1M NaOH). Flash column chromatography was carried out using Merck silica 
gel 60 (0.040-0.063 mm).  
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6.2 Experimental for Chapter 2 
6.2.1 Procedures 
(p-Nitrobenzyl)-2,3,4,6-tetra-O-acetyl-1-thio--D-mannopyranoside 2 
To a solution of 2,3,4,6-tetra-O-acetyl-1-thio-α-D-
mannopyranose 1 (4.0 g, 11.0 mmol) and 4-nitrobenzyl 
bromide (4.7 g, 22.0 mmol) in DMF (anhydrous, 50 mL) was 
added TEA (2.3 mL). After stirring overnight at r.t., the 
reaction mixture was diluted with ethyl acetate (100 mL) and completely washed with 1M HCl (70 mL), 
D.I water (70 mL), and brine (70 mL). The organic phase was dried over Na2SO4, filtered. Filtrate was 
concentrated and purified by flash column chromatography (3:1 → 0:1, n-hexane: ethyl acetate) to 
afford the product as an amorphous solid (4.4 g, 81%). TLC (1:2, n-hexane: ethyl acetate) (Rf 0.7); []
25 
D  = +101.9 (c = 0.5 in CHCl3); 
1H NMR (600 MHz, CDCl3) δH 8.19 (d, J 8.6 Hz, 2H), 7.49 (d, 2H), 
5.32-5.25 (m, 3H), 5.01 (brs, 1H), 4.35-4.28 (m, 2H), 4.06 (dd, J 12.2 Hz, J 2.3Hz, 1H), 3.86 (d, J 13.9 
Hz, 1H), 3.80 (d, 1H) 2.12, 2.11, 2.05, 1.98 (4×s, 12H); 13C NMR (100 MHz, CDCl3) δC 170.5, 169.8, 
169.7, 147.3, 144.5, 130.0, 124.0, 81.0, 70.3, 69.5, 69.4, 66.2, 62.4, 33.8, 20.9, 20.8, 20.7, 20.6; m/z 
(ESI+) calcd. for C21H25NO11SNa [M+Na]+ 522.1, measured 522.2; HRMS (ESI+) calcd. for 
C21H25NO11SNa [M+Na]+ 522.1046, measured 522.1041. 
 
(p-Aminobenzyl)-2,3,4,6-tetra-O-acetyl-1-thio--D-mannopyranoside 3 
(p-Nitrobenzyl)-2,3,4,6-tetra-O-acetyl-1-thio--D-
mannopyranoside 2 (4.0 g, 8.0 mmol) and SnCl2·2H2O 
(9.7 g, 40.1 mmol) were dissolved in EtOH (160 mL). After 
stirring overnight at 70 C under Ar, the reaction mixture 
was poured into ice/water (160 mL), and then pH was 
adjusted by sat. NaHCO3. The residue was extracted with ethyl acetate (200 mL ×2). The organic phase 
was dried over MgSO4, filtered. Filtrate was concentrated and purified by flash column 
chromatography (1:1 → 2:3, nhexane: ethyl acetate) to afford the product (1.6 g, 44%). TLC (1:2, n-
hexane:ethyl acetate) (Rf 0.6); []
25 
D  = +51.0 (c, 1.0 in CHCl3); 
1H NMR (600 MHz, CDCl3) δH 7.08 
(d, J 8.3 Hz, 2H), 6.61 (d, 2H), 5.29-5.27 (m, 3H), 5.08 (brs, 1H), 4.40-4.37 (m, 1H), 4.31 (dd, J 5.4 
Hz, J 12.2 Hz, 1H), 4.02 (dd, J 2.2 Hz, 1H), 3.71-3.64 (m, 4H), 2.11, 2.10, 2.03, 1.95 (4×s, 12H); 13C 
NMR (100 MHz, CDCl3) δC 170.8, 169.9, 169.8, 144.9, 130.2, 127.0, 115.8, 81.2, 70.8, 69.9, 69.0, 
66.5, 62.5, 34.4, 21.0, 20.9, 20.8, 20.7; m/z (ESI+) calcd. for C21H27NO9SNa [M+Na]+ 492.1, measured 
492.3; HRMS (ESI+) calcd. for C21H25NO11SNa [M+Na]+ 492.1304, measured 492.1299.  
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(3-Maleimido-propionyl) (p-aminobenzyl)-2,3,4,6-tetra-O-acetyl-1-thio--D-mannopyranoside 4 
(AMM) 
Mannopyranoside 3 (50 mg, 0.11 mmol) and succinimido 3- 
maleimido-propionoate (34 mg, 0.13 mmol) were dissolved 
in DMF (anhydrous, 5 mL) under Ar. After stirring 
overnight at r.t, the reaction mixture was concentrated in 
vacuo and purified by flash column chromatography (1:1, n-hexane:ethyl acetate) to afford the product 
as a light yellow solid (50 mg, 73%). TLC (1:2, n-hexane:ethyl acetate) (Rf 0.3); []
25 
D  = +10.0 (c = 
1.0 in CHCl3); 1H NMR (600 MHz, CDCl3) δH 7.62 (s, 1H), 7.44 (d, J 8.3 Hz, 2H), 7.23 (d, 2H), 6.70 
(s, 2H), 5.27 (m, 3H), 5.05 (brs, 1H), 4.33-4.36 (m, 1H), 4.27 (dd, J 5.3 Hz, J 12.2 Hz, 1H), 4.00 (dd, J 
2.2 Hz, 1H), 3.91 (t, J 7.0 Hz, 2H), 3.74 (d, J 13.6 Hz, 1H), 3.68 (d, 1H), 2.71 (t, 2H), 2.11, 2.10, 2.03, 
1.95 (4×s, 12H); 13C NMR (150 MHz, CDCl3) δC 170.7, 170.6, 169.9, 169.8, 137.3, 134.3, 132.4, 129.6, 
120.3, 81.0, 70.6, 69.8, 69.0, 66.4, 62.5, 34.2, 34.1, 29.7, 20.9, 20.8, 20.7; m/z (ESI+) calcd. for 
C28H32N2O12SNa [M+Na]+ 643.2, measured 643.6. 
 
(p-Nitrobenzyl)-2,3,4,6-tetra-O-acetyl-1-thio-β-D-galactopyranose 6 
To a solution of 2,3,4,6-tetra-O-acetyl-1-thio-β-D-
galactopyranose 5 (2.0 g, 5.5 mmol) and 4-nitrobenzyl 
bromide (2.4 g, 11.0 mmol) in DMF (anhydrous, 15 mL) 
was added TEA (1.2 mL). After stirring overnight at r.t, 
the reaction mixture was diluted with ethyl acetate (50 mL) and completely washed with 1M HCl (35 
mL), D.I water (35 mL), brine (35 mL). The organic phase was dried over Na2SO4, filtered. The solution 
part was concentrated and purified by flash column chromatography (3:1, n-hexane:ethyl acetate) to 
afford the product as an amorphous solid (2.5 g, 90%). TLC (1:2, n-hexane:ethyl acetate) (Rf 0.7); []
25 
D  = -88.0 (c = 1.0 in CHCl3); 
1H NMR (600 MHz, CDCl3) δH 8.18 (d, J 8.6 Hz, 2H), 7.49 (d, 2H), 
5.17 (at, J 9.4 Hz, 1H), 5.12-5.05 (m, 2H), 4.33 (d, 1H), 4.25-4.22 (m, 1H), 4.16-4.10 (m, 1H), 4.02 (d, 
J 13.1 Hz, 1H), 3.90 (d, 1H), 3.65 (ddd, J 2.3 Hz, 5.0 Hz, 10.0 Hz, 1H), 2.10, 2.04, 2.02, 2.00 (4×s, 
12H); 13C NMR (100 MHz, CDCl3) δC 170.3, 169.9, 169.3, 147.1, 144.9, 129.9, 123.7, 81.7, 75.9, 73.5, 
69.5, 68.2, 62.0, 32.7, 20.6, 20.5, 20.4; m/z (ESI+) calcd. for C21H25NO11SNa [M+Na]+ 522.1, measured 
522.2; HRMS (ESI+) calcd. for C21H25NO11SNa [M+Na]+ 522.1046, measured 522.1045. 
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(p-Aminobenzyl)-2,3,4,6-tetra-O-acetyl-1-thio-β-D-galactopyranose 7 
 
(p-Nitrobenzyl)-2,3,4,6-tetra-O-acetyl-1-thio-β-D-
galactopyranose 6 (1.1 g, 2.1 mmol) and SnCl2·2H2O 
(2.3 g, 10.3 mmol) were dissolved in EtOH (80 mL). 
After stirring overnight at 70 C under Ar, the reaction 
mixture was poured into ice/water (160 mL), and then pH was adjusted by sat. NaHCO3. The residue 
was extracted with ethyl acetate (250 mL ×2). The organic phase was dried over MgSO4, filtered. The 
solution part was concentrated and purified by flash column chromatography (1:1 → 2:3, n-
hexane:ethyl acetate) to afford the product as a light yellow solid (499 mg, 50%). TLC (1:2, n-
hexane:ethyl acetate) (Rf 0.5); []
25 
D  = -53.3 (c = 1.2 in CHCl3); 
1H NMR (600 MHz, CDCl3) δH 7.07 
(d, J 8.3 Hz, 2H), 6.62 (d, 2H), 5.39 (dd, J 3.5 Hz, J 1.2 Hz, 1H), 5.25 (at, J 10.0 Hz, 1H), 4.95 (dd, J 
10.0 Hz, J 3.4 Hz, 1H), 4.26 (d, J 10.0 Hz, 1H), 4.16 (dd, J 6.7 Hz, J 11.4 Hz, 1H), 4.09-4.12 (m, 1H), 
3.86 (d, J 12.8 Hz, 1H), 3.80-3.82 (m, 1H), 3.75 (d, 1H), 3.70 (s, 2H), 1.96, 2.01, 2.06, 2.14 (4×s, 12H); 
13C NMR (100 MHz, CDCl3) δC 170.6, 170.1, 169.4, 145.8, 130.0, 125.9, 115.1, 81.8, 75.6, 73.8, 69.8, 
68.4, 62.2, 33.4, 20.7, 20.6, 20.5; m/z (ESI+) calcd. for C21H27NO9SNa [M+Na]+ 492.1, measured 
492.3; HRMS (ESI+) calcd. for C21H25NO11SNa [M+H]+ 470.1485, measured 470.1482. 
 
(3-Maleimido-propionyl) (p-aminobenzyl)-2,3,4,6-tetra-O-acetyl-1-thio-β-D-galactopyranose 8 
(AGM) 
Galactopyranose 7 (60 mg, 0.13 mmol) and succinimido 
3-maleimido-propionoate (102 mg, 0.38 mmol) were 
dissolved in DMF (anhydrous, 1 mL) under Ar. To the 
reaction mixture were added DCM (0.5 mL) and DIPEA 
(262 μL). After stirring overnight at r.t, the solution part was concentrated in vacuo and purified by 
flash column chromatography (1:2, n-hexane:ethyl acetate) to afford the product (42 mg, 52%). TLC 
(1:2, n-hexane:ethyl acetate) (Rf 0.3); []
25 
D  = -266.0 (c = 1.0 in CHCl3); 
1H NMR (600 MHz, CDCl3) 
δH 7.53 (s, 1H), 7.46 (d, J 8.3 Hz, 2H), 7.25 (d, 2H), 6.72 (s, 2H), 5.41-5.40 (m, 1H), 5.26 (at, J 10.0 
Hz, 1H), 4.96 (dd, J 3.3 Hz, J 10.0 Hz, 1H), 4.27 (d, 1H), 4.14 (dd, J 6.7 Hz, J 11.4 Hz, 1H), 4.08 (dd, 
J 6.5 Hz, 1H), 3.94-3.91 (m, 3H), 3.82-3.79 (m, 2H), 2.73 (t, J 7.0 Hz, 2H), 2.15, 2.07, 2.02, 1.96 (4×s, 
12H); 13C NMR (100 MHz, CDCl3) δC 170.6, 170.5, 170.3, 170.1, 169.7, 137.4, 134.3, 132.8, 129.7, 
120.1, 82.4, 74.4, 71.9, 67.4, 67.2, 61.7, 34.2, 33.4, 29.7, 20.8, 20.7, 20.6; m/z (ESI+) calcd. for 
C28H32N2O12SNa [M+Na]+ 643.2, measured 643.4. 
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6.2.2 Supporting Figures 
 
Figure 6.1. 1H (A) and 13C (B) NMR spectra of (p-Nitrobenzyl)-2,3,4,6-tetra-O-acetyl-1-thio- 
-D-mannopyranoside 2. 
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Figure 6.2. 1H (A) and 13C (B) NMR spectra of (p-Aminobenzyl)-2,3,4,6-tetra-O-acetyl-1-thio--D-
mannopyranoside 3. 
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Figure 6.3. 1H (A) and 13C (B) NMR spectra of (3-Maleimido-propionyl) (p-aminobenzyl)-2,3,4,6-
tetra-O-acetyl-1-thio--D-mannopyranoside 4 (AMM) . 
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Figure 6.4. 1H (A) and 13C (B) NMR spectra of (p-Nitrobenzyl)-2,3,4,6-tetra-O-acetyl-1-thio-β-D-
galactopyranose 6. 
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Figure 6.5. 1H (A) and 13C (B) NMR spectra of (p-Aminobenzyl)-2,3,4,6-tetra-O-acetyl-1-thio-β-D-
galactopyranose 7. 
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Figure 6.6. 1H (A) and 13C (B) NMR spectra of (3-Maleimido-propionyl) (p-aminobenzyl)-2,3,4,6-
tetra-O-acetyl-1-thio-β-D-galactopyranose 8 (AGM) . 
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6.3 Experimental for Chapter 3 
 
6.3.1 Procedures 
Exo-3,4,6-tri-O-acetyl-1,2-O-(1-methoxyethylidene)- β -D-mannopyanoside 3 
2,6-Lutidine (4.2 mL, 36.5 mmol) and anhydrous methanol (2.47 mL, 60.8 
mmol) were added to 2,3,4,6,tetra-O-acetyl--D-mannopyranosyl bromide 
(5g, 12.1 mmol) in anhydrous DCM (20 mL) and the reaction mixture was 
heated to reflux at 40°C. After stirring for 16 h, t.l.c. (1:1, n-hexane:ethyl 
acetate) indicated formation of a product (Rf 0.6) with complete consumption of the starting material 
(Rf  0.7). Water (150 mL) was added to the reaction mixture which was then extracted with DCM (150 
mL  2). The organic layer was washed with brine (100 mL  2), dried over MgSO4, filtered and 
concentrated in vacuo. The residue was purified by flash column chromatography (1:2, n-hexane:ethyl 
acetate) to afford the product as a white crystalline solid (2.8 g, 63%). 1H NMR (CDCl3, 400MHz) δH 
1.72 (s, 3H), 2.03 (s, 3H), 2.05 (s, 3H), 2.10 (s, 3H), 3.26 (s, 3H), 3.67 (ddd, J = 9.5, 4.9, 2.7 Hz, 1H), 
4.12 (dd, J = 12.1, 2.7 Hz, 1H), 4.22 (dd, J = 12.1, 4.9 Hz, 1H), 460 (dd, J = 4.0, 2.6 Hz, 1H), 5.13 (dd, 
J = 9.9, 4.0 Hz, 1H), 5.28 (t, J = 9.7 Hz, 1H), 5.48 (d, J = 2.6 Hz, 1H). 
 
Exo-1,2-O-(1-methoxyethylidene)-β-D-mannopyanoside 4 
Exo-3,4,6-tri-O-acetyl-1,2-O-(1-methoxyethylidene)-β-D-manopyranoside 
3 (1 g, 2.8 mmol) and sodium methoxide (catalytic amount, in situ) were 
added to dry methanol (20 mL). The reaction mixture was stirred under argon 
at RT. After 12 h, Amberlite®  IR 120 hydrogen form washed by MeOH was 
added to the reaction mixture to adjust pH to 7. Then the reaction mixture 
was filtered, and concentrated in vacuo to afford the product as a white solid (490 mg, 75%). m/z (ESI+) 
calcd. for C9H16O7Na [M+Na]+ 259.1, measured 259.1. 
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Exo-3,4,6-tri-O-benzyl-1,2-O-(1-methoxyethylidene)- β-D-mannopyranoside 5 
Benzylbromide (16.1 mL, 135.5 mmol) was added dropwise to a solution of 
Exo-1,2-O-(1-methoxyethylidene)-β-D-manopyranoside (3.2 g, 13.6 mmol) 
4 and sodium hydride (60% dispersion in mineral oil, 227 mg) in anhydrous 
DMF (100 mL) and stirred under argon. After 16 h, t.l.c (1:1, n-hexane:ethyl 
acetate) indicated formation of a product (Rf 0.8) with complete consumption of the starting material 
(Rf 0.0). Methanol (100 mL) was added to quench the reaction mixture, which was then concentrated 
in vacuo. The residue was suspended in water (200 mL) and extracted with diethyl ether (150 mL  2). 
The combined organic layers were washed with brine (100 mL), dried over MgSO4, filtered and 
concentrated in vacuo. The residue was purified by flash column chromatography (3:1, n-hexane:ethyl 
acetate) to afford Exo-3,4,6-tri-O-benzyl-1,2-O-(1-methoxyethylidene)-β-D-mannopyranoside 5 (4.3 g, 
63%). 1H NMR (400 MHz, CDCl3) δH 1.78 (s, 3H), 3.32 (s, 3H), 3.45 (ddd, J = 9.4, 4.4, 2.3 Hz, 1H), 
3.72 – 3.79 (m, 3H), 3.97 (t, J = 9.3 Hz, 1H), 4.43 (dd, J = 4.0, 2.6 Hz, 1H), 4.54 – 4.67 (m, 3H), 4.82 
(d, J = 5.6 Hz, 2H), 4.94 (d, J = 10.8 Hz, 1H), 5.37 (d, J = 2.5 Hz, 1H), 7.24 – 7.47 (m, 15H) ; m/z 
(ESI+) calcd. for C30H34O7Na [M+Na]+ 529.2, measured 529.3. 
1,2-Di-O-acetyl-3,4,6-tri-O-benzyl-D-mannopyranose 6 
Exo-3,4,6-tri-O-benzyl-1,2-O-(1-methoxyethylidene)-β-D-mannopyranoside 
5 (2 g, 3.9 mmol) was stirred in water (20 mL) and acetic acid (10 mL). After 
4 h, t.l.c (1:1, ethyl acetate: n-hexane) indicated formation of two products (Rf 
0.5, 0.6) with complete consumption of the starting material (Rf 0.8). The reaction mixture was diluted 
with ethyl acetate (100 mL) and the layers separated. The aqueous layer was extracted with ethyl acetate 
(50 mL  2), and the combined organic layers washed with sodium hydrogencarbonate (100 ML of a 
saturated aqueous solution), dried over MgSO4, filtered and concentrated in vacuo. The residue was 
coevaporated with toluene and dried in vacuo. The residue was suspended in pyridine (20 mL), cooled 
to 0°C, and acetic anhydride (10 mL) was added dropwise. The reaction mixture was allowed to warm 
to room temperature. After 16 h, t.l.c (1:1, ethyl acetate: n-hexane) indicated formation of a product (Rf 
0.8) with complete consumption of the starting materials (Rf 0.5, 0.6). The reaction mixture was 
concentrated in vacuo to afford 1,2-Di-O-acetyl-3,4,6-tri-O-benzyl-D-mannopyranose 6 (: β, 1:2) (1.7 
g, 80%). 1H NMR (400 MHz, CDCl3) δH 2.10 (s, 3H), 2.12 (s, 3H), 2.20 (s, 3H), 2.25 (s, 3H), 3.61 (ddd, 
J = 9.7, 4.1, 2.2 Hz, 1H), 3.70 – 3.94 (m, 7H), 4.00 – 4.05 (m, 2H), 4.50 – 4.62 (m, 6H), 4.68 – 4.79 (m, 
4H), 4.88 – 4.93 (m, 2H), 5.41 (t, J = 2.4 Hz, 1H), 5.66 (dd, J = 3.2, 1.0 Hz, 1H), 5.78 (d, J = 1.1 Hz, 
1H), 6.17 (d, J = 2.0 Hz, 1H), 7.30 – 7.40 (m, 15H) ; m/z (ESI+) calcd. for C31H34O8Na [M+Na]+ 557.2, 
measured 557.3. 
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2-O-Acetyl-3,4,6-tri-O-benzyl--D-mannopyranose 7 
Benzylamine (0.7 mL, 6.4 mmol) was added to a solution of 1,2-di-O-acetyl-
3,4,6-tri-O-benzyl-D-mannopyranose 6 (1.7 g, 3.2 mmol) in THF (30 mL). 
After 24 h, t.l.c. (2:1, n-hexane:ethyl acetate) indicated formation of a product 
(Rf 0.3) with complete consumption of the starting material (Rf 0.6). The reaction mixture was 
concentrated in vacuo, dissolved in ethyl acetate (300 mL) and washed with ice cold hydrochloric acid 
(100 mL of a 1 M aqueous solution) and sodium hydrogencarbonate (100 mL of a saturated aqueous 
solution). The organic layer was dried over MgSO4, filtered and concentrated in vacuo. The residue was 
purified by flash column chromatography (1,2:ethyl acetate: n-hexane) to afford 2-O-Acetyl-3,4,6-tri-
O-benzyl--D-mannopyranose 7 (1.2 g, 78.5%) 1H NMR (400 MHz, CDCl3) δH 2.15 (s, 3H), 3.74 – 
3.68 (m, 3H), 3.76 (d, J = 6.3 Hz, 1H), 4.04 (dd, J = 9.3, 3.3 Hz, 2H), 4.47 (d, J = 10.9 Hz, 1H), 4.51 
(d, J = 9.1 Hz, 1H), 4.54 (d, J = 8.1 Hz, 1H), 4.61 (d, J = 12.1 Hz, 1H), 4.71 (d, J = 11.2 Hz, 1H), 4.87 
(d, J = 10.9 Hz, 1H), 5.21 (d, J = 1.0 Hz, 1H), 5.37 (dd, J = 3.3, 1.9 Hz, 1H), 7.24 – 7.39 (m, 15H) ; 
m/z (ESI+) calcd. for C29H32O7Na [M+Na]+ 515.2, measured 515.4 
 
2-O-Acetyl-3,4,6-tri-O-benzyl--D-mannopyranosyl trichloroacetimidate 8 
 2-O-Acetyl-3,4,6-tri-O-benzyl--D-mannopyranose 7 (400 mg, 0.81 mmol) 
and trichloroacetonitrile (812 μL, 8.1 mmol) were stirred in anhydrous DCM 
(20 mL) with 4 Å  molecular sieves for 30 min. 1,8-
Diazabicyclo[5,4,0]undec-7ene (6 μL, 0.04 mmol) was added and the 
reaction mixture stirred under argon at RT. After 16 h, t.l.c. (1:1, ethyl acetate: n-hexane), indicated 
formation of a product (Rf 0.7) with complete consumption of the starting material (Rf 0.4). 
Triethylamine (1 mL) was added and the reaction mixture filtered through celite and concentrated in 
vacuo. The residue was purified by flash column chromatography (1:1, ethyl acetate: n-hexane) to 
afford 2-O-Acetyl-3,4,6-tri-O-benzyl--D-mannopyranosyl trichloroacetimidate 8 (330 mg, 64%). 1H 
NMR (400 MHz, CDCl3) δH 2.20 (s, 3H), 3.73 (dd, J = 11.2, 1.7 Hz, 1H), 3.86 (dd, J = 11.2, 3.6 Hz, 
1H), 3.97 – 4.16 (m, 3H), 4.53 (dd, J = 12.3, 9.7 Hz, 2H), 4.60 (d, J = 11.2 Hz, 1H), 4.70 (d, J = 12.0 
Hz, 1H), 4.75 (d, J = 11.2 Hz, 1H), 4.89 (d, J = 10.6 Hz, 1H), 5.51 (t, J = 2.3 Hz, 1H), 6.32 (d, J = 1.9 
Hz, 1H), 7.15 – 7.43 (m, 15H), 8.70 (s, 1H).  
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2’-azidoethyl-2-O-acetyl-3,4,6-tri-O-benzyl--D-mannopyranoside 9 
2-O-acetyl-3,4,6-tri-O-benzyl--D-mannopyranosyl 
trichloroacetimidate 8 (1 g, 1.57 mmol) and 2-azidoethanol (150 mg, 
1.73 mmol) were stirred in anhydrous DCM (20 mL) with 4 Å  
molecular sieves for 30 min. Trimethylsilyl trifuloromethanesulfonate 
(100 μL) was added dropwise and the reaction mixture stirred under argon at RT. After 8 h, the reaction 
mixture was quenched by Triethylamine (100 μL) for 30 min. The reaction mixture was filtered and 
concentrated in vacuo. The residue was purified by flash column chromatography (1:4, ethyl acetate: 
n-hexane) to afford 2’-azidoethyl-2-O-acetyl-3,4,6-tri-O-benzyl--D-mannopyranoside 9 (710 mg, 
80.5%). 1H NMR (400 MHz, CDCl3) δH 2.16 (s, 3H), 3.39 (ddd, J = 5.7, 4.3, 1.3 Hz, 2H), 3.62 (ddd, J 
= 10.5, 5.8, 4.6 Hz, 1H), 3.69 – 3.74 (m. 1H), 3.77 – 3.82 (m, 1H), 3.82 – 3.85 (m, 1H), 3.85 – 3.88 (m, 
1H), 3.90 (dd, J = 7.5, 3.3 Hz, 1H), 4.02 (dd, J = 8.9, 3.4 Hz, 1H), 4.48 (d, J = 10.8 Hz, 1H), 4.52 (d, 
8.0 Hz, 1H), 4.54 (d, , J = 7.1 Hz, 1H), 4.67 (d, J = 10.4 Hz, 1H), 4.70 (d, J = 9.5 Hz, 1H), 4.87 (d, , J 
= 10.8 Hz, 1H), 4.90 (d, J = 1.8 Hz, 1H), 5.39 (dd, J = 3.4, 1.9 Hz 1H), 7.08 – 7.47 (m, 15H) ; m/z 
(ESI+) calcd. for C31H35O7N3Na [M+Na]+ 584.2, measured 584.4. 
 
2’-azidoethyl-3,4,6-tri-O-benzyl--D-mannopyranoside 10  
2’-azidoethyl-2-O-acetyl-3,4,6-tri-O-benzyl--D-
mannopyranoside 9 (380 mg, 0.67 mmol) and sodium methoxide 
(catalytic amount, in situ) were added to anhydrous methanol (10 
mL). The reaction mixture was stirred under argon at RT. After 12 
h, Amberlite®  IR 120 hydrogen form washed by MeOH was added to the reaction mixture to adjust pH 
to 7. Then the reaction mixture was filtered, and concentrated in vacuo to afford 2’-azidoethyl-3,4,6-
tri-O-benzyl--D-mannopyranoside 10 (352 mg, 100%, quantitative yield). 1H NMR (400 MHz, 
CD3OD) δH 3.29 (dt, J = 3.3, 1.6 Hz, 1H), 3.36 (dt, J = 5.8, 3.6 Hz, 2H), 3.59 (ddd, J = 8.7, 6.0, 4.0 Hz, 
1H), 3.66 (t, J = 3.1 Hz, 2H), 3.75 (ddd, J = 9.7, 6.4, 3.7 Hz, 1H), 3.88 – 3.79 (m, 3H), 4.04 (t, J = 2.0 
Hz, 1H), 4.47 (dd, J = 11.4, 9.7 Hz, 2H), 4.55 (dd, J = 11.8, 4.4 Hz, 2H), 4.70 (d, J = 11.7 Hz, 1H), 4.79 
(d, J = 11.0 Hz, 1H), 7.41 – 7.13 (m, 15H) ; m/z (ESI+) calcd. for C29H33O6N3Na [M+Na]+ 542.2, 
measured 542.5. 
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2’-azidoethyl-2-O-acetyl-3,4,6-tri-O-benzyl--D-mannopyranosyl-(1→2)-3,4,6-tri-O-benzyl--D-
manno-pyranoside 11 
2-O-acetyl-3,4,6-tri-O-benzyl--D-mannopyranosyl 
trichloroacetimidate 8 (1.9 g, 3.00 mmol) and 2’-azidoethyl-3,4,6-
tri-O-benzyl--D-mannopyranoside 10 (1.3 g, 2.5 mmol) were 
stirred in anhydrous DCM (20 mL) with 4 Å  molecular sieves for 30 
min. Trimethylsilyl trifuloromethanesulfonate (200 μL) was added 
dropwise and the reaction mixture stirred under argon at RT. After 9 
h, the reaction mixture was quenched with triethylamine (200 μL). After 30 min, the reaction mixture 
was filtered, and concentrated in vacuo. The residue was purified by flash column chromatography (1:4, 
ethyl acetate: n-hexane) to afford 2’-azidoethyl-2-O-acetyl-3,4,6-tri-O-benzyl--D-mannopyranosyl-
(1→2)-3,4,6-tri-O-benzyl--D-manno-pyranoside 11 (1.2 g, 48.3%) ; m/z (ESI+) calcd. for 
C58H63O12Na [M+Na]+ 1016.4, measured 1016.5. 
 
2-aminoethyl--D-mannopyranosyl-(1→2)-D-mannopyranoside 12 
2’-azidoethyl-2-O-acetyl-3,4,6-tri-O-benzyl--D-mannopyranosyl-
(1→2)-3,4,6-tri-O-benzyl--D-manno-pyranoside 11 (300 mg, 0.30 
mmol) and sodium methoxide (catalytic amount, in situ) were added 
to anhydrous methanol (10 mL). The reaction mixture was stirred 
under argon at RT. After 12 h, Amberlite®  IR 120 hydrogen form 
washed by MeOH was added to the reaction mixture to adjust pH to 
7. Then the reaction mixture was filtered, and concentrated in vacuo. The residue was dissolved in 
MeOH (20 mL). Palladium on carbon (5 wt. %) (500 mg) was added to the solution. The reaction 
mixture was flushed with hydrogen five times and stirred at RT under an atmosphere of hydrogen. The 
reaction mixture was filtered through celite®  and concentrated in vacuo to afford 2-aminoethyl--D-
mannopyranosyl-(1→2)-D-mannopyranoside 12 (89%). 1H NMR (400 MHz, CD3OD) δ 5.13 (s, 1H), 
4.99 (s, 1H), 4.01 – 3.83 (m, 6H), 3.76 – 3.60 (m, 6H), 3.60 – 3.49 (m, 3H), 3.32 – 3.29 (m, 1H), 3.19 
(s, 2H). ; m/z (ESI+) calcd. for C14H28O11N [M+H]+ 386.2, measured 386.2. 
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6.3.2 Supporting Figures 
 
Figure 6.7. 1H NMR spectra of Exo-3,4,6-tri-O-acetyl-1,2-O-(1-methoxyethylidene)-β-D-
manopyranoside 3. 
 
Figure 6.8. 1H NMR spectra of Exo-3,4,6-tri-O-benzyl-1,2-O-(1-methoxyethylidene)-β-D-
mannopyranoside 5. 
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Figure 6.9. 1H NMR spectra of 1,2-Di-O-acetyl-3,4,6-tri-O-benzyl-D-mannopyranose 6. 
 
Figure 6.10. 1H NMR spectra of 2-O-Acetyl-3,4,6-tri-O-benzyl--D-mannopyranose 7. 
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Figure 6.11. 1H NMR spectra of 2-O-Acetyl-3,4,6-tri-O-benzyl--D-mannopyranosyl 
trichloroacetimidate 8. 
 
Figure 6.12. 1H NMR spectra of 2’-azidoethyl-2-O-acetyl-3,4,6-tri-O-benzyl--D-mannopyranoside 9. 
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Figure 6.13. 1H NMR spectra of 2’-azidoethyl-3,4,6-tri-O-benzyl--D-mannopyranoside 10. 
 
Figure 6.14. 1H NMR spectra of 2-aminoethyl--D-mannopyranosyl-(1→2)-D-mannopyranoside 12. 
55 
 
6.4 Experimental for Chapter 4 
 
6.4.1 Procedures 
 (4-Pyrenebutanoyl)(p-Aminobenzyl)-2,3,4,6-tetra-O-acetyl-1-thio--D-mannopyranoside 2 
(p-Aminobenzyl)-2,3,4,6-tetra-O-acetyl-1-thio--D-
mannopyranoside 1  (1000 mg, 2.1 mmol) and 1-
pyrenebutyric acid (917 mg, 3.2 mmol) were added to 
dry DMF (30 mL). TBTU (1200 mg, 3.2 mmol) and triethylamine (590 µL, 4.2 mmol) were added to 
the mixture. The reaction mixture was stirred under argon at RT. After stirring for 12 h, the reaction 
mixture was diluted with DCM (100 mL). The mixture was washed with 1M HCl (50 mL) and brine 
(50 mL). The aqueous layer was extracted with dichloromethane (50 mL3). The combined organic 
layer was dried over MgSO4, filtered and concentrated in vacuo. The residue was purified by flash 
column chromatography (3:4, n-hexane:ethyl acetate) to afford the product as a light brown solid (1289 
mg, 82%). m.p.: 105 C; []
25 
D  = +98.5 (c = 1.0 in CH2Cl2); 
1H NMR (CDCl3, 400 MHz) δH 1.97, 2.04, 
2.10 (3×s, 12H), 2.24-2.27 (m, 2H), 2.36 (t, J = 6.9 Hz, 2H), 3.39 (t, J = 7.3 Hz, 2H), 3.68-3.74 (m, 2H), 
4.02 (dd, J = 12.1, 2.2 Hz, 1H), 4.30 (dd, J = 12.1, 5.3 Hz, 1H), 4.37 (m, 1H), 5.07 (brs, 1H), 5.29-5.31 
(m, 3H), 7.20 (d, J = 8.4 Hz, 2H), 7.27 (s, 1H), 7.40 (d, 2H), 7.82 (d, J = 7.8 Hz, 1H), 7.96-8.00 (m, 
3H), 8.06 (m, 2H), 8.14 (d, J = 7.6 Hz, 2H), 8.26 (d, J = 9.3 Hz, 1H); 13C NMR (100 MHz, CDCl3) δC 
20.7, 20.8, 20.9, 27.1, 32.6, 34.1, 36.8, 62.5, 66.4, 69.0, 69.8, 70.6, 81.1, 120.0, 123.4, 124.9, 125.0, 
125.1, 125.9, 126.8, 127.4, 127.5, 128.8, 129.6, 130.0, 130.9, 131.4, 132.4, 135.7, 137.3, 169.8, 169.9, 
170.7, 171.0; m/z (ESI+) calcd. for C41H41NO10SNa [M+Na]+ 762.2, measured 762.4; HRMS (ESI+) 
calcd. for C41H41NO10SNa [M+Na]+ 762.2343, measured 762.2338. 
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 (4-Pyrenebutanoyl)(p-Aminobenzyl)-1-thio--D-mannopyranoside 3 
(4-Pyrenebutanoyl)(p-Aminobenzyl)-2,3,4,6-tetra-O-acetyl-1-
thio--D-mannopyranoside 2 (350 mg, 0.5 mmol) and sodium 
methoxide (catalytic amount, in situ) were added to dry 
methanol (10 mL). The reaction mixture was stirred under argon at RT. After 12h, Amberlite®  IR 120 
hydrogen form washed by MeOH was added to the reaction mixture to adjust pH to 7. Then the reaction 
mixture was filtered, and concentrated in vacuo to afford the product as a light brown solid (270 mg, 
99%). m.p.: 215 C; []
25 
D  = +183 (c = 1.0 in DMF); 
1H NMR (400 MHz, DMSO-d6, aliquot amount 
of D2O) δH 2.05-2.09 (m, 2H), 2.43 (t, J = 7.1 Hz, 2H), 3.32-3.36 (m, 2H), 3.39-3.45 (m, 2H), 3.47-3.51 
(m, 1H), 3.60 (m, 1H), 3.63-3.71 (m, 4H), 4.89 (brs, 1H), 7.23 (d, J = 8.5 Hz, 2H), 7.48 (d, 2H), 7.94 
(d, J = 7.8 Hz, 1H), 8.03 (at, J = 7.6 Hz, 1H), 8.10 (m, 2H), 8.19 (at, J = 8.7 Hz, 2H), 8.23-8.26 (m, 2H), 
δ 8.35 (d, J = 9.3 Hz, 1H); 13C NMR (100 MHz, DMSO-d6) δC 27.3, 32.2, 32.5, 35.9, 61.1, 67.3, 71.5, 
71.7, 74.6, 83.0, 119.1, 123.5, 124.1, 124.2, 124.8, 125.0, 126.1, 126.5, 127.2, 127.4, 127.6, 128.2, 
129.3, 130.4, 130.9, 132.6, 136.4, 138.0, 170.9; m/z (ESI+) calcd. for C33H33NO6SNa [M+Na]+ 594.2, 
measured 594.4; HRMS (ESI+) calcd. for C33H33NO6SNa [M+Na]+ 594.1921, measured 594.1914. 
(4-Pyrenebutanoyl)(p-Aminobenzyl)-2,3,4,6-tetra-O-acetyl-1-thio- β -D-galactopyranoside 5 
(p-Aminobenzyl)-2,3,4,6-tetra-O-acetyl-1-thio-β-D-
galactopyranoside 4 (1000 mg, 2.1 mmol) and 1-pyrenebutyric 
acid (730 mg, 2.5 mmol) were added to dry DMF (30 mL). TBTU 
(815 mg, 2.5 mmol) and triethylamine (590 µL, 4.2 mmol) were added to the mixture. The reaction 
mixture was stirred under Argon at RT. After 12 h, the reaction mixture was diluted with DCM (100 
mL). The mixture was washed with 1M HCl (50 mL) and brine (50 mL). The aqueous layer was 
extracted with DCM (50 mL3). The combined organic layer was dried over MgSO4, filtered and 
concentrated in vacuo. The residue was purified by flash column chromatography (3:4, n-hexane:ethyl 
acetate) to afford the product as a light brown solid (900 mg, 57%). m.p.: 95 C; []
25 
D  = -42.1 (c = 1.0 
in CH2Cl2); 1H NMR (CDCl3, 400 MHz) δH 1.97, 2.00, 2.11 (4×s, 12H), 2.16-2.22 (M, 2H), 2.31 (t, J = 
7.1 Hz, 2H), 3.30 (t, J = 7.3 Hz, 2H), 3.72-3.76 (m, 2H), 3.85-3.88 (m, 1H), 4.00-4.13 (m, 2H), 4.24 (d, 
J = 10.0 Hz, 1H), 4.97 (dd, J = 10.0, 3.3 Hz, 1H), 5.28 (at, J = 10.0 Hz, 1H), 5.38-5.39 (m, 1H), 7.18 
(d, J = 8.3 Hz, 2H), 7.43 (d, 2H), 7.74-7.75 (m, 2H), 7.91-8.01 (m, 5H), 8.07-8.10 (m, 2H), 8.18 (d, J = 
9.3 Hz, 1H); 13C NMR (100 MHz, CDCl3) δC 20.5, 20.6, 20.7, 27.0, 32.4, 33.2, 36.6, 61.5, 67.1, 67.3, 
71.7, 74.3, 82.3, 119.8, 123.2, 124.7, 124.8, 124.9, 125.8, 126.6, 127.2, 127.3, 128.6, 129.5, 129.8, 
130.7, 131.2, 132.3, 135.6, 137.3, 169.6, 169.8, 170.1, 170.2, 170.3, 171.1, 171.2; m/z (ESI+) calcd. 
for C41H41NO10SNa [M+Na]+ 762.2, measured 762.3; HRMS (ESI+) calcd. for C41H41NO10SNa 
[M+Na]+ 762.2343, measured 762.2336. 
57 
 
(4-Pyrenebutanoyl)(p-Aminobenzyl)-1-thio- β -D-galactopyranoside 6 
 
 (p-Aminobenzyl)-2,3,4,6-tetra-O-acetyl-1-thio-β-D-
galactopyranosyl-    pyrenebutanamide 5 (200 mg, 0.3 mmol) 
and sodium methoxide (catalytic amount, in situ) were added to 
dry methanol (10 mL). The reaction mixture was stirred under argon at RT. After 12h, Amberlite®  IR 
120 hydrogen form washed by MeOH was added to the reaction mixture to adjust pH to 7. Then the 
reaction mixture was filtered, and concentrated in vacuo to afford the product as a light brown solid 
(154 mg, 99%). m.p.: 205 C; []
25 
D  = -70 (c = 0.2 in DMSO); 
1H NMR (400 MHz, DMSO-d6, aliquot 
amount of D2O) δH 2.02-2.10 (m, 2H), 2.44 (t, 2H), 3.22 (dd, J = 9.1, 3.3 Hz, 1H), 3.29-3.33 (m, 3H), 
3.41 (at, J = 9.3 Hz, 1H), 3.50–3.59 (m, 2H), 3.69-3.72 (m, 2H), 3.86 (d, J = 12.9 Hz, 1H), 4.02 (d, J = 
9.6 Hz, 1H), 7.24 (d, J = 8.6 Hz, 2H), 7.53 (d, 2H), 7.88 (d, J = 7.9 Hz, 1H), 7.98 (t, J = 7.6 Hz, 1H), 
8.02-8.07 (m, 2H), 8.13 (dd, J = 8.4, 7.4 Hz, 2H), 8.19 (dd, J = 7.7, 3.0 Hz, 2H), 8.32 (d, J = 9.3 Hz, 
1H); 13C NMR (100 MHz, DMSO-d6, aliquot amount of D2O) δC 27.3, 31.9, 32.2, 35.9, 48.6, 60.7, 68.5, 
70.0, 74.8, 79.4, 83.6, 119.0, 123.5, 124.1, 124.2, 124.8, 124.9, 125.0, 126.1, 126.5, 127.3, 127.4, 127.6, 
128.2, 129.3, 130.4, 130.9, 132.8, 136.5, 137.9, 170.9; m/z (ESI+) calcd. for C33H33NO6SNa [M+Na]+ 
594.2, measured 594.8; HRMS (ESI+) calcd. for for C33H33NO6SNa [M+Na]+ 594.1921, measured 
594.1918. 
 
Incubation of Glyco-Pyrene Derivatives on Graphene Device and Lectin Binding. 
Graphene film was deposited to the device, Si wafer and glass wafer. For the Raman spectroscopy and 
atomic force microscopy, Si wafer was used. And glass wafer was used for the UV-Vis spectroscopy. In 
a typical preparation experiment, graphene film on wafer was incubated in 2 g/L of (4-
Pyrenebutanoyl)(p-Aminobenzyl)-1-thio--D-mannopyranoside 3 solution in MeOH for 12h at RT. For 
the protein binding sensing, Concananvalin A (ConA) in 10 mM HEPES, 150 mM NaCl, 5 mM CaCl2 
buffer solution (0.1 mL/mg, pH 7.5) was used. Each sample was thoroughly rinsed with MeOH before 
analysis to remove excess amount of 3 on the sample. Finally, rinsed sample was dried over the air. 
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6.4.2 Supporting Figures 
 
(a) 
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Figure 6.15. (a) 1H and (b) 13C NMR spectra of mannopyranoside 2. 
 
(b) 
(a) b
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Figure 6.16. (a) 1H and (b) 13C NMR spectra of mannopyranoside 3. 
 
 
Figure 6.17. (a) COSY and (b) HSQC spectra of mannopyranoside 3. 
 
(a) 
(b) 
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(a) 
(b) 
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Figure 6.18. (a) 1H and (b) 13C NMR spectra of galactopyranoside 5. 
 
(a) 
(b) 
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Figure 6.19. (a) 1H and (b) 13C NMR spectra of galactopyranoside 6. 
 
 
Figure 6.20. (a) COSY and (b) HSQC spectra of galactopyranoside 6. 
(a) 
(b) 
64 
 
 
 
6.5 Experimental for Chapter 5 
6.5.1 Procedures 
Mono-6-(p-toluenesulfonyl)-6-deoxy- β-cyclodextrin (β-CD-Ts) 1  
In a 1-L double-necked, round-bottom flask, β-CD hydrate (20.0 g, 
35.2 mmol) was dissolved in deionized water (450 mL) by heating to 
60°C with vigorous stirring. To the resulting milky suspension was 
added 1-(p toluenesulfonyl) imidazole (12 g, 54mmol). After 2 h, a 
solution of sodium hydroxide (9 g, 225 mmol) of 25mL of water was 
added over 20 min. After 10 min, 1-(p-toluenesulfonyl)-imidazole was 
separated by filtration. Filtrant was concentrated and dried overnight. 
1HNMR (500MHz, DMSO-d6, d): 2.42 (3H, s), 3.20–3.65 (40H, 
overlap with HDO, m), 4.15–4.23 (1H, m), 4.30–4.38 (2H, m), 4.40–4.54 (2H, m), 4.50 (3H, br s), 4.76 
(2H, br s), 4.84 (4H, br s), 5.62–5.84 (14H,m), 7.43 (2H, d, J = 7.75Hz), 7.73 (2H, d, J = 7.75Hz); 
MALDI-TOF MS (m/z) calculated for C49H76O37SNa, 1311.4; found 1311.5 for [M+Na]+. 
Mono-6-azide-deoxy-6-β-cyclodextrin (β-CD-N3) 2  
In a 1-L-double-necked, round-bottomed flask, β-Ts-CD (5 g, 3.9 
mmol) was dissolved in deionized water (500mL) and added sodium 
azide (5 g, 76.9 mmol) into the flask by heating to100°C with oil bath. 
The reaction mixture was refluxed overnight in the oil bath and cool 
down the reaction to room temperature. The filtered reaction solution 
was concentrated at least 95% of water under reduced pressure using 
a rotary evaporator. To the concentrated filtrate was added 1,1,2,2-
tetrachloroethane dropwise (5 mL) and the resultant mixture was 
stirred for 30 min. The residue was extracted, washed and concentrated in vacuo. The powder was 
recrystallized and dried at 60 °C in vacuo to generate β-CD-N3. 13CNMR (125MHz, D2O, d): 53.2, 62.3, 
74.3, 74.4, 75.4, 83.4, 104.4; ESI-MS (m/z): calculated for C42H69O34N3, 1182.4; found, 1182.5 for 
[M+Na]+. 
65 
 
Succinimido 3-maleimido-propionate 4 
β-Alanine (2.7 g, 30 mmol) and maleic anhydride (2.9 g, 30 mmol) was 
dissolved in DMF (anhydrous, 30 mL) at RT under Ar. After stirring for 2 
h, the reaction mixture was cooled down to 0 °C and NHS (4.2 g, 37 mmol) 
was added followed by DCC (12.9 g, 63 mmol). After 10 min, the ice bath 
was removed and the mixture was vigorously stirred for overnight. White 
urea precipitate was filtered out and filtrate was concentrated, then poured into ice/water. The 
precipitate was rinsed with water, and the residue was purified by flash column chromatography (n-
hexane:EtOAc, 1:1→0:1) to afford the product as a white solid (4.0 g, 50%). 1H NMR (600 MHz, 
DMSO-d6) δ 2.79 (4H, s), 3.04 (2H, t, J = 6.8 Hz), 3.74 (2H, t, J 6.8 Hz), 7.04 (2H, s). 
 
N-Propargyl 3-maleimido-propionamide (PMP) 5 
To a solution of succinimido 3-maleimido-propionoate (400 mg, 1.50 
mmol) in THF (10 mL) was added propargylamine (106 mL, 4.95 mmol) 
at 0 °C. After stirring overnight at RT, the reaction mixture was diluted in 
DCM (100 mL) and extracted with water (100 mL). The organic phase was 
dried under Na2SO4, filtered, and concentrated in vacuo. The residue was 
filtered and rinsed with DCM. The solution part was concentrated and 
purified by flash column chromatography (n-hexane:EtOAc, 1:2→0:1) to afford the titled product as a 
white solid (17 mg, 6%). 1H NMR (600 MHz, CDCl3) δ 2.22 (1H, t, J 2.5 Hz), 2.55 (2H, t, J 7.2 Hz), 
3.84 (2H, t, J 7.2 Hz), 4.01 (2H, dd, J 2.5, 5.2 Hz), 6.02 (1H, s), 6.70 (2H, s); 13C NMR (150 MHz, 
CDCl3) δ 29.3, 34.2, 34.5, 17.8, 79.5, 134.4, 169.4, 170.6; ESI-MS (m/z): calculated for C10H10N2NaO3, 
229.1; found 228.8 [M+H]+. 
FITC-AD Conjugate  
To a solution of FITC-isothiocyanate (52 mg, 0.134 mmol) in DMF (anhydrous, 
2 mL) was added 1-adamantylamine (20 mg, 0.134 mmol) and DIPEA (50 mL, 
0.302 mmol). After stirring for 16 h under Ar, the reaction mixture was 
concentrated in vacuo and purified byflash column chromatography (n-
hexane:EtOAc, 2:1→1:5) to afford the product as an orange colored solid 
(quantitative). 1H NMR (600 MHz, acetone-d6) δ 1.73 (6H, m), 2.10 (3H, s), 2.36-
2.37 (6H, m), 6.63 (2H, dd, J 2.4, 8.7Hz), 6.74 (2H, d, J 8.7 Hz), 6.70 (2H, d, J 2.4 Hz),7.18 (1H, d, J 
8.2 Hz), 7.83 (1H, dd, J 1.8, 8.2 Hz), 8.27 (1H, d, J 1.8 Hz), 8.97 (1H, s), 8.99 (2H, s); ESI-MS (m/z): 
calculated for C31H28N2O5S, 540.2; found 540.7 [M+H]+. 
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6.5.2 Supporting Figures 
 
Figure 6.21 (A) 1H NMR spectrum of N-Propargyl 3-maleimidopropionamide (PMP). (B) 13C NMR 
spectrum of PMP. 
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Figure 6.22. 1H NMR spectrum of β-CD-Ts. (B) 13C NMR spectrum of β-CD-N3. 
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Figure 6.23. 1H NMR of FITC-AD conjugate. 
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